Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Preference of New Trientine 4HCl Formulation vs Standard-of-Care in Wilson's Disease
NCT07010575Phase 2Completed
- Sponsor
- Orphalan
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trientine in Wilson's disease, sponsored by Orphalan. Primary endpoint: Patient preference, convenience and satisfaction at Week 8. Started Jul 2025; status: completed.
02
Drugs
trientine
03
Conditions
Wilson's disease
Beyond the preview
Go deeper on NCT07010575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010575.